(CercleFinance.com) – The stock ended the day up more than 1%. UBS raises its recommendation on Roche from ‘sell’ to ‘neutral’ despite a price target lowered from 380 to 365 Swiss francs, a new target implying a limited downside potential of 4% for the title of the Swiss health group.
“After the devaluation, low growth now seems integrated”, judges the broker, estimating that Roche is trading with a discount of 15% on the sector, this “better reflects its profile and the challenge of developing a revenue base of this size ‘.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
